Trial Outcomes & Findings for Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP (NCT NCT05366855)

NCT ID: NCT05366855

Last Updated: 2026-03-27

Results Overview

Recruitment status

TERMINATED

Study phase

PHASE3

Target enrollment

42 participants

Primary outcome timeframe

All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product.

Results posted on

2026-03-27

Participant Flow

Subjects who completed the Week 4 Visit of Study ANB019-301 and had a GPPPGA score of 0 or 1 on Day 1 were randomized 1:1 to receive imsidolimab or placebo in a double-blind manner. Subjects who completed the Week 4 Visit but did not have a GPPPGA score of 0 or 1 received open-label imsidolimab. Subjects who exited the study at the Week 1 Visit (after primary endpoint assessment) or later received open-label rescue therapy.

Participant milestones

Participant milestones
Measure	ANB019-301 Imsidolimab Responder + ANB019-302 Imsidolimab 200 mg SC Randomized to subcutaneous 200 mg imsidolimab Q4W	ANB019-301 Imsidolimab Responder + ANB019-302 Placebo SC Randomized to subcutaneous placebo Q4W	ANB019-301 Imsidolimab Partial Responder + ANB019-302 Imsidolimab 200 mg SC Open-label subcutaneous 200 mg imsidolimab Q4W	ANB019-301 Imsidolimab Need for Rescue + ANB019-302 Any Therapy Any available therapy	ANB019-301 Placebo Responder + ANB019-302 Placebo SC Randomized to subcutaneous placebo SC Q4W	ANB019-301 Placebo Partial Responder + ANB019-302 Imsidolimab 200 mg SC Open-label subcutaneous 200 mg imsidolimab Q4W	ANB019-301 Placebo Need for Rescue + ANB019-302 Imsidolimab 750 mg IV/200 mg SC Intravenous imsidolimab 750 mg loading dose followed by subcutaneous 200 mg imsidolimab Q4W
Overall Study STARTED	8	7	8	5	1	4	9
Overall Study COMPLETED	0	0	0	5	0	0	0
Overall Study NOT COMPLETED	8	7	8	0	1	4	9

Reasons for withdrawal

Reasons for withdrawal
Measure	ANB019-301 Imsidolimab Responder + ANB019-302 Imsidolimab 200 mg SC Randomized to subcutaneous 200 mg imsidolimab Q4W	ANB019-301 Imsidolimab Responder + ANB019-302 Placebo SC Randomized to subcutaneous placebo Q4W	ANB019-301 Imsidolimab Partial Responder + ANB019-302 Imsidolimab 200 mg SC Open-label subcutaneous 200 mg imsidolimab Q4W	ANB019-301 Placebo Responder + ANB019-302 Placebo SC Randomized to subcutaneous placebo SC Q4W	ANB019-301 Placebo Partial Responder + ANB019-302 Imsidolimab 200 mg SC Open-label subcutaneous 200 mg imsidolimab Q4W	ANB019-301 Placebo Need for Rescue + ANB019-302 Imsidolimab 750 mg IV/200 mg SC Intravenous imsidolimab 750 mg loading dose followed by subcutaneous 200 mg imsidolimab Q4W
Overall Study Withdrawal by Subject	0	1	1	0	1	1
Overall Study Adverse Event	1	2	0	1	1	0
Overall Study Physician Decision	7	4	7	0	2	7
Overall Study Protocol Violation	0	0	0	0	0	1

Baseline Characteristics

Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	ANB019-301 Imsidolimab Responder + ANB019-302 Placebo SC n=7 Participants Randomized to subcutaneous placebo Q4W	ANB019-301 Imsidolimab Partial Responder + ANB019-302 Imsidolimab 200 mg SC n=8 Participants Open-label subcutaneous 200 mg imsidolimab Q4W	ANB019-301 Imsidolimab Need for Rescue + ANB019-302 Any Therapy n=5 Participants Any available therapy	ANB019-301 Placebo Responder + ANB019-302 Imsidolimab 200 mg SC Randomized to subcutaneous 200 mg imsidolimab Q4W	ANB019-301 Placebo Responder + ANB019-302 Placebo SC n=1 Participants Randomized to subcutaneous placebo SC Q4W	ANB019-301 Placebo Partial Responder + ANB019-302 Imsidolimab 200 mg SC n=4 Participants Open-label subcutaneous 200 mg imsidolimab Q4W	ANB019-301 Placebo Need for Rescue + ANB019-302 Imsidolimab 750 mg IV/200 mg SC n=9 Participants Intravenous imsidolimab 750 mg loading dose followed by subcutaneous 200 mg imsidolimab Q4W	Total n=42 Participants Total of all reporting groups	ANB019-301 Imsidolimab Responder + ANB019-302 Imsidolimab 200 mg SC n=8 Participants Randomized to subcutaneous 200 mg imsidolimab Q4W
Age, Continuous	52 Years STANDARD_DEVIATION 18.36 • n=62 Participants	54.6 Years STANDARD_DEVIATION 14.73 • n=123 Participants	41 Years STANDARD_DEVIATION 12.21 • n=53 Participants	—	22 Years STANDARD_DEVIATION NA • n=120 Participants	31.0 Years STANDARD_DEVIATION 6.48 • n=18 Participants	32.3 Years STANDARD_DEVIATION 13.78 • n=12 Participants	42.9 Years STANDARD_DEVIATION 16.57 • n=6 Participants	45 Years STANDARD_DEVIATION 15.71 • n=56 Participants
Sex: Female, Male Female	6 Participants n=62 Participants	4 Participants n=123 Participants	5 Participants n=53 Participants	0 Participants n=654 Participants	1 Participants n=120 Participants	4 Participants n=18 Participants	6 Participants n=12 Participants	32 Participants n=6 Participants	6 Participants n=56 Participants
Sex: Female, Male Male	1 Participants n=62 Participants	4 Participants n=123 Participants	0 Participants n=53 Participants	0 Participants n=654 Participants	0 Participants n=120 Participants	0 Participants n=18 Participants	3 Participants n=12 Participants	10 Participants n=6 Participants	2 Participants n=56 Participants
Race/Ethnicity, Customized Asian	3 Participants n=62 Participants	3 Participants n=123 Participants	3 Participants n=53 Participants	0 Participants n=654 Participants	0 Participants n=120 Participants	3 Participants n=18 Participants	6 Participants n=12 Participants	23 Participants n=6 Participants	5 Participants n=56 Participants
Race/Ethnicity, Customized White	4 Participants n=62 Participants	5 Participants n=123 Participants	0 Participants n=53 Participants	0 Participants n=654 Participants	1 Participants n=120 Participants	1 Participants n=18 Participants	3 Participants n=12 Participants	17 Participants n=6 Participants	3 Participants n=56 Participants
Race/Ethnicity, Customized Black or African American	0 Participants n=62 Participants	0 Participants n=123 Participants	1 Participants n=53 Participants	0 Participants n=654 Participants	0 Participants n=120 Participants	0 Participants n=18 Participants	0 Participants n=12 Participants	1 Participants n=6 Participants	0 Participants n=56 Participants
Race/Ethnicity, Customized Other	0 Participants n=62 Participants	0 Participants n=123 Participants	1 Participants n=53 Participants	0 Participants n=654 Participants	0 Participants n=120 Participants	0 Participants n=18 Participants	0 Participants n=12 Participants	1 Participants n=6 Participants	0 Participants n=56 Participants
Region of Enrollment Malaysia	3 Participants n=62 Participants	1 Participants n=123 Participants	0 Participants n=53 Participants	0 Participants n=654 Participants	0 Participants n=120 Participants	2 Participants n=18 Participants	3 Participants n=12 Participants	12 Participants n=6 Participants	3 Participants n=56 Participants
Region of Enrollment Thailand	0 Participants n=62 Participants	1 Participants n=123 Participants	3 Participants n=53 Participants	0 Participants n=654 Participants	0 Participants n=120 Participants	1 Participants n=18 Participants	3 Participants n=12 Participants	9 Participants n=6 Participants	1 Participants n=56 Participants
Region of Enrollment Poland	1 Participants n=62 Participants	3 Participants n=123 Participants	0 Participants n=53 Participants	0 Participants n=654 Participants	0 Participants n=120 Participants	0 Participants n=18 Participants	1 Participants n=12 Participants	5 Participants n=6 Participants	0 Participants n=56 Participants
Region of Enrollment Morocco	0 Participants n=62 Participants	0 Participants n=123 Participants	0 Participants n=53 Participants	0 Participants n=654 Participants	1 Participants n=120 Participants	0 Participants n=18 Participants	0 Participants n=12 Participants	3 Participants n=6 Participants	2 Participants n=56 Participants
Region of Enrollment Turkey	1 Participants n=62 Participants	0 Participants n=123 Participants	0 Participants n=53 Participants	0 Participants n=654 Participants	0 Participants n=120 Participants	0 Participants n=18 Participants	1 Participants n=12 Participants	3 Participants n=6 Participants	1 Participants n=56 Participants
Region of Enrollment United States	0 Participants n=62 Participants	1 Participants n=123 Participants	1 Participants n=53 Participants	0 Participants n=654 Participants	0 Participants n=120 Participants	1 Participants n=18 Participants	0 Participants n=12 Participants	3 Participants n=6 Participants	0 Participants n=56 Participants
Region of Enrollment Taiwan	0 Participants n=62 Participants	1 Participants n=123 Participants	0 Participants n=53 Participants	0 Participants n=654 Participants	0 Participants n=120 Participants	0 Participants n=18 Participants	0 Participants n=12 Participants	2 Participants n=6 Participants	1 Participants n=56 Participants
Region of Enrollment Tunisia	1 Participants n=62 Participants	0 Participants n=123 Participants	0 Participants n=53 Participants	0 Participants n=654 Participants	0 Participants n=120 Participants	0 Participants n=18 Participants	1 Participants n=12 Participants	2 Participants n=6 Participants	0 Participants n=56 Participants
Region of Enrollment France	0 Participants n=62 Participants	0 Participants n=123 Participants	1 Participants n=53 Participants	0 Participants n=654 Participants	0 Participants n=120 Participants	0 Participants n=18 Participants	0 Participants n=12 Participants	1 Participants n=6 Participants	0 Participants n=56 Participants
Region of Enrollment Georgia	0 Participants n=62 Participants	1 Participants n=123 Participants	0 Participants n=53 Participants	0 Participants n=654 Participants	0 Participants n=120 Participants	0 Participants n=18 Participants	0 Participants n=12 Participants	1 Participants n=6 Participants	0 Participants n=56 Participants
Region of Enrollment Spain	1 Participants n=62 Participants	0 Participants n=123 Participants	0 Participants n=53 Participants	0 Participants n=654 Participants	0 Participants n=120 Participants	0 Participants n=18 Participants	0 Participants n=12 Participants	1 Participants n=6 Participants	0 Participants n=56 Participants
GPPPGA Score at Baseline Moderate (3)	7 Participants n=62 Participants	5 Participants n=123 Participants	5 Participants n=53 Participants	0 Participants n=654 Participants	0 Participants n=120 Participants	3 Participants n=18 Participants	8 Participants n=12 Participants	33 Participants n=6 Participants	5 Participants n=56 Participants
GPPPGA Score at Baseline Severe (4)	0 Participants n=62 Participants	3 Participants n=123 Participants	0 Participants n=53 Participants	0 Participants n=654 Participants	1 Participants n=120 Participants	1 Participants n=18 Participants	1 Participants n=12 Participants	9 Participants n=6 Participants	3 Participants n=56 Participants

PRIMARY outcome

Timeframe: All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product.

Population: No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.

Outcome measures

Outcome measures
Measure	ANB019-301 Imsidolimab Responder + ANB019-302 Imsidolimab 200 mg SC n=8 Participants Randomized to subcutaneous 200 mg imsidolimab Q4W	ANB019-301 Imsidolimab Responder + ANB019-302 Placebo SC n=7 Participants Randomized to subcutaneous placebo Q4W	ANB019-301 Imsidolimab Partial Responder + ANB019-302 Imsidolimab 200 mg SC n=8 Participants Open-label subcutaneous 200 mg imsidolimab Q4W	ANB019-301 Imsidolimab Need for Rescue + ANB019-302 Any Therapy n=5 Participants Any available therapy	ANB019-301 Placebo Responder + ANB019-302 Imsidolimab 200 mg SC Randomized to subcutaneous 200 mg imsidolimab Q4W	ANB019-301 Placebo Responder + ANB019-302 Placebo SC n=1 Participants Randomized to subcutaneous placebo SC Q4W	ANB019-301 Placebo Partial Responder + ANB019-302 Imsidolimab 200 mg SC n=4 Participants Open-label subcutaneous 200 mg imsidolimab Q4W	ANB019-301 Placebo Need for Rescue + ANB019-302 Imsidolimab 750 mg IV/200 mg SC n=9 Participants Intravenous imsidolimab 750 mg loading dose followed by subcutaneous 200 mg imsidolimab Q4W
Incidence of Adverse Events	8 Participants	6 Participants	7 Participants	1 Participants	0 Participants	1 Participants	3 Participants	8 Participants

SECONDARY outcome

Timeframe: Week 24

Population: The modified intent-to-treat (mITT) population including all participants that were randomized (1:1) to treatment (imsidolimab or placebo) in a double-blinded manner.

Percentages are calculated using FCS imputation. The Generalized Pustular Psoriasis Physician's Global Assessment (GPPPGA) is a physician-based assessment of the overall disease severity of GPP at the time of evaluation (specifically pustules, erythema, and scaling/crusting of pustular psoriasis lesions). The GPPPGA is graded on a 5-point scale, ranging from 0 (clear) to 4 (severe). GPPPGA Scale: 0 = Clear, 1 = Almost clear, 2 = Mild, 3 = Moderate, 4 = Severe.

Outcome measures

Outcome measures
Measure	ANB019-301 Imsidolimab Responder + ANB019-302 Imsidolimab 200 mg SC n=8 Participants Randomized to subcutaneous 200 mg imsidolimab Q4W	ANB019-301 Imsidolimab Responder + ANB019-302 Placebo SC n=8 Participants Randomized to subcutaneous placebo Q4W	ANB019-301 Imsidolimab Partial Responder + ANB019-302 Imsidolimab 200 mg SC Open-label subcutaneous 200 mg imsidolimab Q4W	ANB019-301 Imsidolimab Need for Rescue + ANB019-302 Any Therapy Any available therapy	ANB019-301 Placebo Responder + ANB019-302 Imsidolimab 200 mg SC Randomized to subcutaneous 200 mg imsidolimab Q4W	ANB019-301 Placebo Responder + ANB019-302 Placebo SC Randomized to subcutaneous placebo SC Q4W	ANB019-301 Placebo Partial Responder + ANB019-302 Imsidolimab 200 mg SC Open-label subcutaneous 200 mg imsidolimab Q4W	ANB019-301 Placebo Need for Rescue + ANB019-302 Imsidolimab 750 mg IV/200 mg SC Intravenous imsidolimab 750 mg loading dose followed by subcutaneous 200 mg imsidolimab Q4W
Percentage of Subjects Maintaining GPPPGA Score of 0 or 1	100 Percentage of subjects (%)	64.4 Percentage of subjects (%)	—	—	—	—	—	—

SECONDARY outcome

Timeframe: From Day 1 until termination of study

Population: The modified intent-to-treat (mITT) population including all participants that were randomized (1:1) to treatment (imsidolimab or placebo) in a double-blinded manner.

GPP flare was defined by a GPPPGA ≥3 (moderate) in subjects who had previously achieved a GPPPGA score of 0 (clear) or 1 (almost clear).

Outcome measures

Outcome measures
Measure	ANB019-301 Imsidolimab Responder + ANB019-302 Imsidolimab 200 mg SC n=8 Participants Randomized to subcutaneous 200 mg imsidolimab Q4W	ANB019-301 Imsidolimab Responder + ANB019-302 Placebo SC n=8 Participants Randomized to subcutaneous placebo Q4W	ANB019-301 Imsidolimab Partial Responder + ANB019-302 Imsidolimab 200 mg SC Open-label subcutaneous 200 mg imsidolimab Q4W	ANB019-301 Imsidolimab Need for Rescue + ANB019-302 Any Therapy Any available therapy	ANB019-301 Placebo Responder + ANB019-302 Imsidolimab 200 mg SC Randomized to subcutaneous 200 mg imsidolimab Q4W	ANB019-301 Placebo Responder + ANB019-302 Placebo SC Randomized to subcutaneous placebo SC Q4W	ANB019-301 Placebo Partial Responder + ANB019-302 Imsidolimab 200 mg SC Open-label subcutaneous 200 mg imsidolimab Q4W	ANB019-301 Placebo Need for Rescue + ANB019-302 Imsidolimab 750 mg IV/200 mg SC Intravenous imsidolimab 750 mg loading dose followed by subcutaneous 200 mg imsidolimab Q4W
Kaplan-Meier Estimate for Time to First GPP Flare Recurrence (Weeks)	NA Weeks Not applicable as there were no events in the time-to-event analysis.	42.3 Weeks Interval 4.1 to 64.0	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Week 24

Population: The modified intent-to-treat (mITT) population including all participants that were randomized (1:1) to treatment (imsidolimab or placebo) in a double-blinded manner.

Percentages are calculated using FCS imputation. GPP flare was defined by a GPPPGA ≥3 (moderate) in subjects who had previously achieved a GPPPGA score of 0 (clear) or 1 (almost clear)

Outcome measures

Outcome measures
Measure	ANB019-301 Imsidolimab Responder + ANB019-302 Imsidolimab 200 mg SC n=8 Participants Randomized to subcutaneous 200 mg imsidolimab Q4W	ANB019-301 Imsidolimab Responder + ANB019-302 Placebo SC n=8 Participants Randomized to subcutaneous placebo Q4W	ANB019-301 Imsidolimab Partial Responder + ANB019-302 Imsidolimab 200 mg SC Open-label subcutaneous 200 mg imsidolimab Q4W	ANB019-301 Imsidolimab Need for Rescue + ANB019-302 Any Therapy Any available therapy	ANB019-301 Placebo Responder + ANB019-302 Imsidolimab 200 mg SC Randomized to subcutaneous 200 mg imsidolimab Q4W	ANB019-301 Placebo Responder + ANB019-302 Placebo SC Randomized to subcutaneous placebo SC Q4W	ANB019-301 Placebo Partial Responder + ANB019-302 Imsidolimab 200 mg SC Open-label subcutaneous 200 mg imsidolimab Q4W	ANB019-301 Placebo Need for Rescue + ANB019-302 Imsidolimab 750 mg IV/200 mg SC Intravenous imsidolimab 750 mg loading dose followed by subcutaneous 200 mg imsidolimab Q4W
Percentage of Subjects With Zero Recurrence of GPP Flare	100.0 Percentage of subjects (%) Interval 2.9 to 70.6	63.3 Percentage of subjects (%)	—	—	—	—	—	—

Adverse Events

ANB019-301 Imsidolimab Responder + ANB019-302 Imsidolimab 200 mg SC

Serious events: 0 serious events

Other events: 8 other events

Deaths: 0 deaths

ANB019-301 Imsidolimab Responder + ANB019-302 Placebo SC

Serious events: 1 serious events

Other events: 6 other events

Deaths: 0 deaths

ANB019-301 Imsidolimab Partial Responder + ANB019-302 Imsidolimab 200 mg SC

Serious events: 2 serious events

Other events: 7 other events

Deaths: 0 deaths

ANB019-301 Imsidolimab Need for Rescue + ANB019-302 Any Therapy

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

ANB019-301 Placebo Responder + ANB019-302 Imsidolimab 200 mg SC

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

ANB019-301 Placebo Responder + ANB019-302 Placebo SC

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

ANB019-301 Placebo Partial Responder + ANB019-302 Imsidolimab 200 mg SC

Serious events: 0 serious events

Other events: 3 other events

Deaths: 0 deaths

ANB019-301 Placebo Need for Rescue + ANB019-302 Imsidolimab 750 mg IV/200 mg SC

Serious events: 2 serious events

Other events: 8 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	ANB019-301 Imsidolimab Responder + ANB019-302 Imsidolimab 200 mg SC n=8 participants at risk Randomized to subcutaneous 200 mg imsidolimab Q4W	ANB019-301 Imsidolimab Responder + ANB019-302 Placebo SC n=7 participants at risk Randomized to subcutaneous placebo Q4W	ANB019-301 Imsidolimab Partial Responder + ANB019-302 Imsidolimab 200 mg SC n=8 participants at risk Open-label subcutaneous 200 mg imsidolimab Q4W	ANB019-301 Imsidolimab Need for Rescue + ANB019-302 Any Therapy n=5 participants at risk Any available therapy	ANB019-301 Placebo Responder + ANB019-302 Imsidolimab 200 mg SC Randomized to subcutaneous 200 mg imsidolimab Q4W	ANB019-301 Placebo Responder + ANB019-302 Placebo SC n=1 participants at risk Randomized to subcutaneous placebo SC Q4W	ANB019-301 Placebo Partial Responder + ANB019-302 Imsidolimab 200 mg SC n=4 participants at risk Open-label subcutaneous 200 mg imsidolimab Q4W	ANB019-301 Placebo Need for Rescue + ANB019-302 Imsidolimab 750 mg IV/200 mg SC n=9 participants at risk Intravenous imsidolimab 750 mg loading dose followed by subcutaneous 200 mg imsidolimab Q4W
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Basal Cell Carcinoma	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	14.3% 1/7 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Blood and lymphatic system disorders Nephrogenic anaemia	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	12.5% 1/8 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Infections and infestations Arthritis bacterial	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	11.1% 1/9 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Investigations Blood creatine phosphokinase increased	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	12.5% 1/8 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Skin and subcutaneous tissue disorders Pustular psoriasis	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	11.1% 1/9 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.

Other adverse events

Other adverse events
Measure	ANB019-301 Imsidolimab Responder + ANB019-302 Imsidolimab 200 mg SC n=8 participants at risk Randomized to subcutaneous 200 mg imsidolimab Q4W	ANB019-301 Imsidolimab Responder + ANB019-302 Placebo SC n=7 participants at risk Randomized to subcutaneous placebo Q4W	ANB019-301 Imsidolimab Partial Responder + ANB019-302 Imsidolimab 200 mg SC n=8 participants at risk Open-label subcutaneous 200 mg imsidolimab Q4W	ANB019-301 Imsidolimab Need for Rescue + ANB019-302 Any Therapy n=5 participants at risk Any available therapy	ANB019-301 Placebo Responder + ANB019-302 Imsidolimab 200 mg SC Randomized to subcutaneous 200 mg imsidolimab Q4W	ANB019-301 Placebo Responder + ANB019-302 Placebo SC n=1 participants at risk Randomized to subcutaneous placebo SC Q4W	ANB019-301 Placebo Partial Responder + ANB019-302 Imsidolimab 200 mg SC n=4 participants at risk Open-label subcutaneous 200 mg imsidolimab Q4W	ANB019-301 Placebo Need for Rescue + ANB019-302 Imsidolimab 750 mg IV/200 mg SC n=9 participants at risk Intravenous imsidolimab 750 mg loading dose followed by subcutaneous 200 mg imsidolimab Q4W
Infections and infestations Urinary tract infection	12.5% 1/8 • Number of events 2 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	28.6% 2/7 • Number of events 2 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	25.0% 1/4 • Number of events 3 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Infections and infestations Bronchitis	12.5% 1/8 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	12.5% 1/8 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	100.0% 1/1 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Infections and infestations Upper respiratory tract infection	12.5% 1/8 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	28.6% 2/7 • Number of events 5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	12.5% 1/8 • Number of events 3 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	50.0% 2/4 • Number of events 3 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	33.3% 3/9 • Number of events 4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Infections and infestations COVID-19	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	28.6% 2/7 • Number of events 2 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	11.1% 1/9 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Infections and infestations Conjunctivitis	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	14.3% 1/7 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Infections and infestations Folliculitis	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	14.3% 1/7 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Infections and infestations Sinusitis	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	14.3% 1/7 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Infections and infestations Urinary tract candidiasis	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	100.0% 1/1 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Infections and infestations Infection	12.5% 1/8 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Skin and subcutaneous tissue disorders Psoriasis	12.5% 1/8 • Number of events 2 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	28.6% 2/7 • Number of events 2 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	50.0% 2/4 • Number of events 2 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	22.2% 2/9 • Number of events 2 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Skin and subcutaneous tissue disorders Pruritus	12.5% 1/8 • Number of events 2 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	12.5% 1/8 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	11.1% 1/9 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Skin and subcutaneous tissue disorders Erythema	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	14.3% 1/7 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Skin and subcutaneous tissue disorders Eczema	12.5% 1/8 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	11.1% 1/9 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Skin and subcutaneous tissue disorders Acne	12.5% 1/8 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Skin and subcutaneous tissue disorders Neurodermatitis	12.5% 1/8 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Skin and subcutaneous tissue disorders Rosacea	12.5% 1/8 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Investigations C-reactive protein increased	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	14.3% 1/7 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	12.5% 1/8 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	22.2% 2/9 • Number of events 2 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Investigations Blood creatine phosphokinase increased	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	14.3% 1/7 • Number of events 2 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	11.1% 1/9 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Investigations Alanine aminotransferase increased	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	14.3% 1/7 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Investigations Aspartate aminotransferase increased	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	14.3% 1/7 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Investigations Blood pressure increased	12.5% 1/8 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Blood and lymphatic system disorders Anaemia	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	14.3% 1/7 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	11.1% 1/9 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Blood and lymphatic system disorders Lymphopenia	12.5% 1/8 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	100.0% 1/1 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Blood and lymphatic system disorders Leukopenia	12.5% 1/8 • Number of events 3 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Musculoskeletal and connective tissue disorders Psoriatic arthropathy	12.5% 1/8 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	12.5% 1/8 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	11.1% 1/9 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Musculoskeletal and connective tissue disorders Back pain	12.5% 1/8 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	20.0% 1/5 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
General disorders Pyrexia	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	14.3% 1/7 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	12.5% 1/8 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	25.0% 1/4 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	11.1% 1/9 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
General disorders Influenza like illness	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	14.3% 1/7 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
General disorders Injection site haemorrhage	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	14.3% 1/7 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Metabolism and nutrition disorders Diabetes mellitus	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	12.5% 1/8 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	100.0% 1/1 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Nervous system disorders Headache	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	28.6% 2/7 • Number of events 6 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	25.0% 1/4 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Respiratory, thoracic and mediastinal disorders Cough	12.5% 1/8 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	25.0% 1/4 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	14.3% 1/7 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Respiratory, thoracic and mediastinal disorders Nasal congestion	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	14.3% 1/7 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	14.3% 1/7 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Respiratory, thoracic and mediastinal disorders Productive cough	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	14.3% 1/7 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Gastrointestinal disorders Abdominal distension	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	14.3% 1/7 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Injury, poisoning and procedural complications Heat stroke	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	14.3% 1/7 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Endocrine disorders Adrenal insufficiency	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	100.0% 1/1 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	11.1% 1/9 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Injury, poisoning and procedural complications Joint injury	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	14.3% 1/7 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Ear and labyrinth disorders Vertigo	12.5% 1/8 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Immune system disorders Seasonal allergy	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	14.3% 1/7 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Infections and infestations Candida Infection	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	14.3% 1/7 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Skin and subcutaneous tissue disorders Dry skin	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	22.2% 2/9 • Number of events 3 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Skin and subcutaneous tissue disorders Pustular psoriasis	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	12.5% 1/8 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	25.0% 1/4 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Blood and lymphatic system disorders Iron deficiency anaemia	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	11.1% 1/9 • Number of events 2 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Immune system disorders Allergy to arthropod bite	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	11.1% 1/9 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Skin and subcutaneous tissue disorders Angioedema	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	11.1% 1/9 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Injury, poisoning and procedural complications Arteriovenous fistula thrombosis	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	12.5% 1/8 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Injury, poisoning and procedural complications Arthropod bite	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	12.5% 1/8 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Infections and infestations Asymptomatic bacteriuria	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	11.1% 1/9 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Investigations Blood potassium decreased	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	11.1% 1/9 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Investigations Blood triglycerides increased	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	25.0% 1/4 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Infections and infestations Body tinea	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	25.0% 1/4 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Infections and infestations Cellulitis	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	12.5% 1/8 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Infections and infestations Dermatophytosis of nail	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	12.5% 1/8 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Skin and subcutaneous tissue disorders Diffuse alopecia	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	25.0% 1/4 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Nervous system disorders Dizziness	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	11.1% 1/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Infections and infestations Furuncle	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	11.1% 1/9 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Gastrointestinal disorders Gastrointestinal disorder	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	12.5% 1/8 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Vascular disorders Haematoma	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	12.5% 1/8 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Injury, poisoning and procedural complications Hand fracture	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	12.5% 1/8 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Blood and lymphatic system disorders Hyperleukocytosis	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	11.1% 1/9 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Metabolism and nutrition disorders Hyperlipidaemia	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	12.5% 1/8 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Metabolism and nutrition disorders Hypertriglyceridaemia	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	11.1% 1/9 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Infections and infestations Influenza	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	25.0% 1/4 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Investigations Lymphocyte count decreased	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	12.5% 1/8 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Gastrointestinal disorders Nausea	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	11.1% 1/9 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Infections and infestations Onychomycosis	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	12.5% 1/8 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Musculoskeletal and connective tissue disorders Osteoarthritis	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	12.5% 1/8 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Infections and infestations Otitis externa	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	11.1% 1/9 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Infections and infestations Papilloma viral infection	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	11.1% 1/9 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Surgical and medical procedures Polypectomy	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	20.0% 1/5 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Skin and subcutaneous tissue disorders Skin plaque	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	11.1% 1/9 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Cardiac disorders Supraventricular tachycardia	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	11.1% 1/9 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Ear and labyrinth disorders Tinnitus	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	11.1% 1/9 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Investigations Troponin T increased	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	12.5% 1/8 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Skin and subcutaneous tissue disorders Urticaria	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/4 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	11.1% 1/9 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.
Infections and infestations Viral rash	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/7 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/8 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/5 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	— 0/0 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	25.0% 1/4 • Number of events 1 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.	0.00% 0/9 • All Adverse Events (AEs) were collected from Day 1 of 302 up to the final Safety Follow-up Visit (Week 116) regardless of seriousness or relationship to investigational product. No ANB019-301 placebo responders were randomized to receive imsidolimab 200 mg SC.

Additional Information

Vanda Pharmaceuticals Inc.

Phone: 202-734-3400

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place